NIPPON CHEMIPHAR CO., LTD. Logo

NIPPON CHEMIPHAR CO., LTD.

Develops generic drugs, allergy treatments, and novel pharmaceuticals for a global market.

4539 | T

Overview

Corporate Details

ISIN(s):
JP3701600003
LEI:
Country:
Japan
Address:
千代田区岩本町二丁目2番3号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Nippon Chemiphar Co., Ltd. is a pharmaceutical company engaged in the manufacture, sale, import, and export of ethical pharmaceuticals, diagnostic agents, and health-related products. The company's business is centered on three strategic pillars: the development of high-quality generic drugs; the commercialization of innovative products derived from its core technologies in the allergy field; and the creation of novel drugs based on proprietary technologies and know-how, such as alkalization therapy. Nippon Chemiphar aims to provide solutions that help people maintain their health and is actively pursuing the global expansion of its three core business areas.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 02:32
Report Publication Announcement
確認書
Japanese 8.7 KB
2025-11-13 02:32
Interim Report
半期報告書-第94期(2025/04/01-2026/03/31)
Japanese 221.2 KB
2025-06-20 03:58
Post-Annual General Meeting Information
臨時報告書
Japanese 30.9 KB
2025-06-20 03:57
Governance Information
内部統制報告書-第93期(2024/04/01-2025/03/31)
Japanese 23.8 KB
2025-06-20 03:57
Registration Form
確認書
Japanese 8.6 KB
2025-06-20 03:56
Registration Form
有価証券報告書-第93期(2024/04/01-2025/03/31)
Japanese 1.2 MB
2024-11-13 01:21
Interim Report
半期報告書-第93期(2024/04/01-2025/03/31)
Japanese 223.1 KB
2024-11-13 01:21
Interim Report
確認書
Japanese 8.7 KB
2024-06-24 08:03
Regulatory News Service
臨時報告書
Japanese 18.7 KB
2024-06-24 03:28
Post-Annual General Meeting Information
臨時報告書
Japanese 25.6 KB
2024-06-24 03:27
Registration Form
確認書
Japanese 8.6 KB
2024-06-24 03:26
Governance Information
内部統制報告書-第92期(2023/04/01-2024/03/31)
Japanese 23.2 KB
2024-06-24 03:24
Registration Form
有価証券報告書-第92期(2023/04/01-2024/03/31)
Japanese 1.2 MB
2024-02-13 04:31
Report Publication Announcement
確認書
Japanese 8.7 KB
2024-02-13 04:30
Quarterly Report
四半期報告書-第92期第3四半期(2023/10/01-2023/12/31)
Japanese 230.5 KB

Automate Your Workflow. Get a real-time feed of all NIPPON CHEMIPHAR CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NIPPON CHEMIPHAR CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NIPPON CHEMIPHAR CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Bioengineering solutions to accelerate life sciences research, from gene synthesis to cell lines.
South Korea
355690
aTYR PHARMA INC Logo
Developing novel medicines for fibrosis and inflammation using tRNA synthetase biology.
United States of America
ATYR
Aura Biosciences, Inc. Logo
Developing virus-like therapies to selectively destroy solid tumors in ocular & urologic oncology.
United States of America
AURA
Aurinia Pharmaceuticals Inc. Logo
Biopharma developing therapies for autoimmune and kidney diseases like lupus nephritis.
United States of America
AUPH
AURORA CANNABIS INC Logo
A global producer and seller of medical and recreational cannabis and derivative products.
United States of America
ACB
Autolus Therapeutics plc Logo
Develops programmed CAR T-cell therapies for cancer and autoimmune diseases.
United States of America
AUTL
AVADEL PHARMACEUTICALS PLC Logo
Develops once-at-bedtime therapies for adults with narcolepsy using innovative drug delivery.
United States of America
AVDL
Avidity Biosciences, Inc. Logo
Pioneering targeted RNA therapies that treat the root cause of rare muscle diseases.
United States of America
RNA
Axsome Therapeutics, Inc. Logo
Biopharma company developing novel therapies for central nervous system (CNS) conditions.
United States of America
AXSM
AYTU BIOPHARMA, INC Logo
Specialty pharma advancing innovative medicines for CNS diseases like MDD and ADHD.
United States of America
AYTU

Talk to a Data Expert

Have a question? We'll get back to you promptly.